The rates of all-cause mortality were 0.1084 with ramipril and 0.1402 with placebo. The difference was -0.0318 (95% confidence interval, CI: -0.0534 - -0.0102).
The rates of myocardial infarction were 0.1023 with ramipril and 0.1295 with placebo. The difference was -0.0271 (95% CI: -0.0481 - -0.0062).
The rates of stroke were 0.0420 with ramipril and 0.0611 with placebo. The difference was -0.0190 (95% CI: -0.0335 - -0.0045).
The rates of revascularisation were 0.1405 with ramipril and 0.1645 with placebo. The difference was -0.0240 (95% CI: -0.0476 - -0.0005).
The rates of overt nephropathy were 0.0647 with ramipril and 0.0842 with placebo. The difference was -0.0195 (95% CI: -0.0367 - -0.0023).
The rates of congestive heart failure were 0.1095 with ramipril and 0.1334 with placebo. The difference was -0.0239 (95% CI: -0.0453 - -0.0025).
The rates of transient ischaemic attack were 0.0442 with ramipril and 0.0588 with placebo. The difference was -0.0145 (95% CI: -0.0290 - -0.0001).
The rates of worsening angina were 0.2008 with ramipril and 0.2244 with placebo. The difference was -0.0236 (95% CI: -0.0505 - -0.0032).
The estimated life expectancy for survivors at the end of the trial was 5.56 years (range: 5.15 - 6).